Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer

Neoplasia

Volumn 9, Issue 10, 2007, Pages 788-796

  Turcotte, Simon ^a,b   Forget, Marie Andrée ^a   Beauseigle, Diane ^a   Nassif, Edgar ^a,b   Lapointe, Réjean ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Breast cancer; Dikkopf 1 (DKK1); Expression profile; Prostate derived Ets transcription factor (PDEF); Tumor biomarkers

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; MESSENGER RNA; PROSTATE DERIVED ETS TRANSCRIPTION FACTOR; PROTEIN; PROTEIN DIKKOPF 1; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DENSITY; RISK FACTOR;

EID: 35448931036     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07460     Document Type: Article

References (27)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
2. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98, 10869-10874.
3. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee S-J, Baker J, Cronin M, Walker M, Watson D, Shak S, et al. (2005). Prognostic role of a multigene reverse transcriptase - PCR assay in patients with nodenegative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 11, 3315-3319.
4. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24, 3726-3734 (Epub 2006 May 23).
5. Feldman RJ, Sementchenko VI, and Watson DK (2002). The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation and carcinogenesis. Anticancer Res 23, 2125-2132.
6. Oikawa T (2004). Ets transcription factors: possible targets for cancer therapy. Cancer Sci 95, 626-633.
7. Kurpios NA, Sabolic NA, Sheperd TG, Fidalgo GN, and Hassell JA (2003). Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 8, 177-190.
8. Man AK, Young LJ, Tynan JA, Lesperance J, Eqeblad M, Werb Z, Hauser CA, Muller WJ, Cardiff RD, and Oshima RG (2003). Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol 23, 8614-8625.
9. Behrens P, Rothe M, Wellmann A, Krischler J, and Wernert N (2001). The Ets-1 transcription factor is up-regulated together with MMP1 and MMP9 in the stroma of pre-invasive breast cancer. J Pathol 194, 43-50.
10. Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, and Benz CC (2000). Ets regulation of the erbB2 promoter. Oncogene 19, 6490-6502.
11. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, et al. (2000). PDEF, a novel prostate epithelium-specific Ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 275, 1216-1225.
12. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J, Davis JN, and Meyers S (2006). RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 97, 1-17.
13. Ghadersohi A and Sood AK (2001). Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin Cancer Res 7, 2731-2738.
14. Gunawardane RN, Sgroi DC, Wrobel CN, Koh E, Daley GQ, and Brugge JS (2005). Novel role for PDEF in epithelial cell migration and invasion. Cancer Res 65, 11572-11580.
15. Mitas M, Mikhitarian K, Hoover L, Lockett MA, Kelley L, Hill A, Gillanders WE, and Cole DJ (2002). Prostate-specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes. Br J Cancer 86, 899-904.
16. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, and Watson DK (2003). PDEF expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 63, 4626-4631.
17. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, and Nozaki M (2000). Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 60, 1348-1352.
18. Turner DP, Moussa O, Sauane M, Fisher PB, and Watson DK (2007). Prostate-derived Ets factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 67, 1618-1625.
19. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, and Libermann TA (2007). Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67, 4219-4226.
20. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, and Li F (2007). Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 102, 19-30 (Epub 2006 Aug 8).
21. Lepage S and Lapointe R (2006). Melanosomal targeting sequences from gp100 are essential for MHC class II - restricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res 66, 2423-2432.
22. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
23. Pfaffl MW, Horgan GW, and Dempfle L (2002). Relative Expression Software Tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30, e36.
24. Forget MA, Turcotte S, Beauseigle D, Godin-Ethier J, Pelletier S, Martin J, Tanguay S, and Lapointe R (2007). The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 96, 646-653.
25. Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, Ito T, Ito H, Miyagi Y, Nakayama H, et al. (2007). Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 67, 2517-2525.
26. Abdul-Rasool S, Kidson SH, Panieri E, Dent D, Pillay K, and Hanekom GS (2006). An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes. J Clin Pathol 59, 289-297.
27. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, et al. (2006). Classification and risk stratification of invasive breast carcinomas using a realtime quantitative RT-PCR assay. Breast Cancer Res 8, R23 (Epub 2006 Apr 20).